Abstract Library

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,

#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours

Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Passegger C, Kump P, Haybäck J, Lipp R, Niederle B,

Keywords: Gastrointestinal neuroendocrine tumour, chicken chorioallantoic membrane assay, Patient derived tumour xenografts,

#1088 Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up

Introduction: Digestive Neuroendocrine Neoplasms (DNENs) express in 80% of cases somatostatin receptors (SSTRs) detected by functional imaging tests (FITs). FITs are needed at diagnosis to define therapy but their role in follow-up (FU) is unclear

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Merola E

Authors: Merola E, Panzuto F, Capurso G, Kump P, Lipp R,

Keywords: Metastatic, DNENs, follow-up, FIT, CT,

#1060 Fifty-Three Year-Old-Male with a Symptomatic Ileocecal Carcinoid: An Individual Follow-Up of 14 Yrs with 5 Different Anti-Proliferative Therapies

Introduction: Only limited reports exist about sequence of different anti-tumor therapies in patients with neuroendocrine tumors (NETs) after primary surgery.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kump P

Authors: Kump P, Suppan C, Spindelböck W, Krejs G, Lipp R,

Keywords: targeted therapy, sequence therapy, neuroendocrine tumor, gep-net,

#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)

Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Keplinger F, Spindelböck W, Kump P, Heber D, Wießpeiner U,

Keywords: neuroendocrine tumor, DOPA-PET, somatostatin receptor scintigraphy, progression,